The Indian Journal of Pediatrics

, Volume 71, Issue 11, pp 973–977 | Cite as

Oral itraconazole in treatment of candidemia in a pediatric intensive care unit

  • Sunit C. Singhi
  • Thimmapuram C. S. Reddy
  • Arunaloke Chakrabarti
Original Article

Abstract

Objective: To examine efficacy of itraconazole in the treatment of candidemia in critically ill children.Methods: We studied retrospectively cases of candidemia seen consecutively in our Pediatric Intensive Care Unit (PICU) over three and half year.Candida isolates from those patients included.Candida albicans- 19, C.tropicalis-31,C. guillermondii- 9,C.krusei- 4 andC. glabrata-1Results: Of the 64 patients, 48 (75%) had symptoms suggestive of septicemia and 16 had no symptoms suggestive of septicemia. No antifungal therapy was given to asymptomatic patients; they recovered from candidemia without development of any sequelae. Of the 48 symptomatic patients 11 died before results of fungal culture became available and antifungal therapy could be started. Thirty seven patients were treated with itraconazole (10 mg/kg/day orally or through gastric tube). Seven (18.9 %) of 37 patients died, 3 within first week of antifungal therapy. Thirty (81%) patients recovered; microbiological cure was noted on average by day 14 (range 4–30 days). The mean ±SD duration of therapy in patients who responded was 24 ±7 days (range 21–42 days). None had any major side effect.Conclusion: We conclude that oral itraconazole may be effective in treatment of candidemia in children in a PICU where non-C.albicans Candida species constituted majority (70%) of allCandida isolates.

Key words

Antifungal therapy Candida Candidemia Itraconazole Intensive care units 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chakrabarti A, Chander J, Kasturi P, Panigrahi D. Candidemia: A 10 years study in an Indian teaching hospital.Mycoses 1992; 35: 47–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Jarwis WR. Epidemiology of nosocomial infections in pediatric patients.Pediatr Infect Dis 1987; 6: 344–350.Google Scholar
  3. 3.
    Jarwis WR. Epidemiology of nosocomial fungal infections, with emphasis onCandida species.Clin Infect Dis 1995; 20: 1526–1530.Google Scholar
  4. 4.
    Chiu NC, Chugh YF, Huang FY. Pediatric nosocomial fungal infections.Southeast Asian J Trop Med Public Health 1997; 28: 191–195.PubMedGoogle Scholar
  5. 5.
    Weese Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: A case control study.Pediatr Infect Dis J 1987; 6: 190–196.PubMedGoogle Scholar
  6. 6.
    Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained.Pediatr Infect Dis J 1989; 8: 99–104.PubMedCrossRefGoogle Scholar
  7. 7.
    Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital acquired candidemia.Arch Intern Med 1989; 149: 2349–2353.PubMedCrossRefGoogle Scholar
  8. 8.
    Dato VM, Dajani AS. Candidemia in children with central venous catheters: Role of catheter removal on amphotericin B therapy.Pediatr Infect Dis J 1990; 9: 309–314.PubMedCrossRefGoogle Scholar
  9. 9.
    Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole.Expert Opin Pharmacother 2000; 1: 287–304.PubMedCrossRefGoogle Scholar
  10. 10.
    Dupont B, Drouhet E. Early experience with itraconazolein vitro and in patients” Pharmacokinetic studies and clinical results.Rev Infect Dis 1987; 9: (Suppl) 71–76.Google Scholar
  11. 11.
    Dismukes WE. Azole antifungal drug: Old and new.Ann Intern Med 1988; 109: 177–179.PubMedGoogle Scholar
  12. 12.
    De Rosso JQ, Gupta AK. Oral itraconazole therapy for superficial, subcutaneous, and systemic infections. A panoramic view.Postgrad Med 1999,Spec No: 46–52Google Scholar
  13. 13.
    Del Rosso JQ, Zellis S, Gupta AK. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections.J Am Osteopath Assoc 1998; 98: 497–502.PubMedGoogle Scholar
  14. 14.
    Nucci M, Biasoli I, Akiti Tet al. A double blind randomized, placebo-controlled trial of itraconazole capsule as antifungal prophylaxis for neutropenic patients.Clin Infect Dis 2000; 30: 300–305.PubMedCrossRefGoogle Scholar
  15. 15.
    Crutchfield CE, Lewis EJ. The successful treatment of oral candidiasis (thrush) in a pediatric patient using itraconazole.Pediatr Dermatol 1997; 14: 246.PubMedGoogle Scholar
  16. 16.
    Aanpreung P, Veerakul G. Itraconazole for treatment of oral candidosis in pediatric cancer patients.J Med Assoc Thai 1997; 80: 358–362.PubMedGoogle Scholar
  17. 17.
    Martin MV. The use of fluconazole and itraconazole in treatment of Candidaalbicans infection; a review.J Antimicrob Chemother 1999; 44: 429–437.PubMedCrossRefGoogle Scholar
  18. 18.
    Sciacca A, Betta P, Cilauro S, Saporito A, Tina LG. Oral administration of itraconazole in a case of neonatal hepatic candidiasis.Pediatr Med Chir 1995; 17: 173–175.PubMedGoogle Scholar
  19. 19.
    Hiranandani M, Singhi SC, Kaur I, Chakrabarti A. Disseminated candidiasis in a pediatric intensive care unit.Indian Pediatr 1994; 32: 1159–1166.Google Scholar
  20. 20.
    Bhandari V, Narang A, Kumar B, Nair PMC, Bhakoo ON. Itraconazole therapy for disseminated candidiasis in a very low birth weight neonate.J Pediatr Child Health 1992; 28: 323–324.Google Scholar
  21. 21.
    Moore GS, Jaciow DM. Yeast identification. In: Mycology for clinical laboratory. Reston, VA: Reston, 1979;169–201.Google Scholar
  22. 22.
    Stamos JK, Rowley AH. Candidemia in a pediatric population.Clin Infect Dis 1995; 20: 571–575.PubMedGoogle Scholar
  23. 23.
    Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: prevention and management.Drug Safety 1992; 7: 323–363.PubMedCrossRefGoogle Scholar
  24. 24.
    Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy.N Engl J Med 1994; 330: 263–272.PubMedCrossRefGoogle Scholar
  25. 25.
    Jannsen Pharmaceuticals. Sporanox® (Itraconazole) oral solution and capsules. Titusvile, NJ 1997, Feb.Google Scholar
  26. 26.
    Berenguer J, Buck M, Witebsky Fet al. Lysisrcentrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection.Diagn Microbiol Infect Dis 1993; 17: 103–109.PubMedCrossRefGoogle Scholar
  27. 27.
    Pacheo-Rios A, Avila-Figueroa C, Nobigrot-Keinman D, Santos JI. Mortality associated with systemic candidiasis in children.Arch Med Res 1997 Summer; 28: 229–32.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2004

Authors and Affiliations

  • Sunit C. Singhi
    • 1
  • Thimmapuram C. S. Reddy
    • 1
  • Arunaloke Chakrabarti
    • 1
    • 2
  1. 1.Departments of PediatricsPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Departments of Medical MicrobiologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations